| Drug Name: | Nadolol (42200-33-9) |
|---|---|
| PubChem ID: | 39147 |
| SMILES: | CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O |
| InchiKey: | VWPOSFSPZNDTMJ-UCWKZMIHSA-N |
| Therapeutic Category: | Adrenergic Agents, Adrenergic Antagonists, Adrenergic beta-Antagonists, Anti-Arrhythmia Agents, Antihypertensive Agents, Autonomic Agents, Cardiovascular Agents, Neurotransmitter Agents, Peripheral Nervous System Agents, Sympatholytics |
| Molecular Weight (dalton) | : | 309.406 |
| LogP | : | 0.6348 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 81.95 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Increased Beta-Blockade | CYP2D6 (P10635) | Increased beta-blockade [ ADR Type 1 ] | Drugs in special patient groups: clinical importance of genomics in drug effects In: Carruthers GS, Hoffmann BB,Melmon KL, Nierenberg DW |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category